Glycomine, a biotechnology company focused on developing new therapies for orphan diseases, has closed a $68 million Series B financing.

The financing was led by new investors, Abingworth and Sanofi Ventures, and joined by RiverVest Venture Partners and Remiges Ventures. In addition, all previous Series B investors- Novo Holdings A/S, Asahi Kasei Pharma Ventures, Mission BioCapital, Sanderling Ventures, and Chiesi Ventures- participated.